[Principles in the performance of chemotherapy in dispensary group VI children and adolescents].
Based on the annual reports of Moscow tuberculosis dispensaries, the analysis of their follow-up of dispensary registration group VI patients, the authors have developed preventive chemotherapy regimens in relation to the specific features of tuberculin sensitivity, the presence or absence of additional risk factors (concomitant somatic diseases, social risk factors). Regimen I (1 antituberculous drug (isoniazid) for 3 months) may be used in dispensary registration groups VIA and VIB patients without additional risk factors. Regimen II (2 antituberculous drugs (isoniazid + pyrazinamide/ethambutol) for 3 months) may be employed in dispensary registration groups VIA and VIB patients with additional risk factors, as well as in children from dispensary registration group VIB, whether additional risk factors are present or absent. A repeated course of preventive chemotherapy regimen II is indicated when tuberculin sensitivity is increased or a hyperergic reaction is retained after termination of treatment in patients having additional risk factors.
Ovsiankina
E S
ES
Gubkina
M F
MF
Kuz'mina
I K
IK
Stakheeva
L B
LB
Borodina
N N
NN
Zaletina
E Iu
EIu
D000293:Adolescent; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D010045:Outpatients; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000517:prevention & control*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid